0.241  -0.002 (-0.82%)		06-15 16:00
Open: 0.2377 High: 0.2534 Volume: 8,317,499		Pre. Close: 0.243 Low: 0.23 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	0.14	1-year :	0.19
Resists	First :	0.12	Second :	0.17
Pivot price	0.07
Supports	First :	0.06	Second :	0.05
MAs	MA(5) :	0.07	MA(20) :	0.07
	MA(100) :	0.32	MA(250) :	0.62
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	31.8	D(3) :	27.4
RSI	RSI(14): 40.5
52-week	High :	1.77	Low :	0.05

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PTE ] has closed above bottom band by 27.8%. Bollinger Bands are 81.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.09 - 0.09	0.09 - 0.09
Low:	0.07 - 0.07	0.07 - 0.07
Close:	0.07 - 0.07	0.07 - 0.07

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Tue, 27 Dec 2022
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company - PR Newswire

Thu, 11 Aug 2022
PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update - PR Newswire

Fri, 13 May 2022
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE® - PR Newswire

Sun, 15 Mar 2020
Earnings Release: Here's Why Analysts Cut Their PolarityTE, Inc. Price Target To US$10.17 - Yahoo Finance

Wed, 04 Sep 2019
PolarityTE Appoints Peter Cohen as Chairman of the Board - PR Newswire

Fri, 10 May 2019
PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE - BioSpace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	-47.8
EBITDA (p.s.)	172174
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.